BridgeBio Pharma (NASDAQ:BBIO) & Parnell Pharmaceuticals (OTCMKTS:PARNF) Head to Head Contrast

Parnell Pharmaceuticals (OTCMKTS:PARNF) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Volatility & Risk

Parnell Pharmaceuticals has a beta of 27.78, indicating that its share price is 2,678% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.

Earnings and Valuation

This table compares Parnell Pharmaceuticals and BridgeBio Pharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parnell Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BridgeBio Pharma	$235.81 million	43.37	-$535.76 million	($4.09)	-13.08

Parnell Pharmaceuticals has higher earnings, but lower revenue than BridgeBio Pharma.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Parnell Pharmaceuticals and BridgeBio Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parnell Pharmaceuticals	0	0	0	0	0.00
BridgeBio Pharma	0	0	17	0	3.00

BridgeBio Pharma has a consensus price target of $63.35, indicating a potential upside of 18.42%. Given BridgeBio Pharma’s stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Parnell Pharmaceuticals.

Profitability

This table compares Parnell Pharmaceuticals and BridgeBio Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Parnell Pharmaceuticals	N/A	N/A	N/A
BridgeBio Pharma	-329.25%	N/A	-85.69%

Insider & Institutional Ownership

99.8% of BridgeBio Pharma shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

BridgeBio Pharma beats Parnell Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About Parnell Pharmaceuticals

Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal – U.S., Production Animal – Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for enhancing cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product for the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also offers mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.

About BridgeBio Pharma

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.